No quarterly revenue total was found in CEL-SCI CORPORATION's SEC filings.
Cel-Sci Corporation (CVM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$4.0 million. As of Jun 30, 2026 it held $6.5 million in cash and investments and $7.9 million in total debt.
Revenue
—
Net income
$-5.67M
-0.0% vs year-ago quarter
Operating cash flow
$-4.03M
-2.3% vs year-ago quarter
Free cash flow
$-4.03M
-2.3% vs year-ago quarter
EPS
$-0.47
+65.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
17.59M
+155.6% vs year-ago quarter
Net cash
$-1.37M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CVM (NYSE)
- Fiscal year ends
- September 30
- Incorporated in
- CO
- Headquarters
- Vienna, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 725363
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.6M | -$5.3M | -$5.4M | -$6.0M | -$5.5M |
| Net income | -$5.7M | -$5.5M | -$5.5M | -$6.1M | -$5.7M |
| Diluted EPS | -$0.47 | -$0.67 | -$0.68 | -$0.87 | -$1.36 |
| Operating cash flow | -$4.0M | -$4.0M | -$4.0M | -$4.7M | -$3.9M |
| Free cash flow | -$4.0M | -$4.0M | -$4.0M | -$4.7M | -$3.9M |
| Total assets | $21.4M | $17.7M | $22.9M | $28.2M | $20.3M |
| Total liabilities | $10.4M | $10.8M | $11.8M | $12.2M | $13.3M |
| Stockholders' equity | $11.0M | $6.9M | $11.1M | $16.0M | $7.0M |
| Cash and investments | $6.5M | $1.9M | $6.3M | $11.0M | $1.8M |
| Total debt | $7.9M | $8.5M | $9.1M | $15.1M | $10.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 2, 2026 | Sep 30, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 16, 2026 | Jun 14, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 14, 2026 | May 11, 2026 |
All 1007 Cel-Sci Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.